Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.56 |
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065179 | 0.82 | SLC6A4 (0.57) | SLC6A4SLC6A2HTR2AKCNH2ALDH1A1 | |
| SCHEMBL7211583 | 0.80 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL9447156 | 0.75 | GAA (0.66) | ALDH1A1 | |
| SCHEMBL8877774 | 0.75 | CYP3A4 (0.49) | ALDH1A1 | |
| SCHEMBL17164822 | 0.75 | NPC1 (0.61) | ALDH1A1 | |
| SCHEMBL5417525 | 0.73 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL31238882 | 0.73 | NPC1 (0.53) | ALDH1A1 | |
| SCHEMBL19892685 | 0.73 | NPC1 (0.53) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5417304 | 0.72 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL13463403 | 0.72 | AURKA (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1449380-A | Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors | PFIZER LTD (US) | 2003-10-15 | — | — | CN | claimed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | claimed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | claimed |
| CN-1449380-A | Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors | PFIZER LTD (US) | 2003-10-15 | — | — | CN | disclosed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | SLC6A4 5/4885SLC6A2 9/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.